How to buy Takeda Pharmaceutical (TAK) shares in Australia
Learn how to easily invest in Takeda Pharmaceutical shares.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Takeda Pharmaceutical Company Limited is a drug manufacturers-specialty & generic business with stocks listed in the US. Takeda Pharmaceutical shares (TAK) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was US$16.89 – a decrease of 1.52% over the previous week. Here's how to invest if you're based in Australia.
How to buy shares in Takeda Pharmaceutical
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Takeda Pharmaceutical. Find the share by name or ticker symbol: TAK. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Takeda Pharmaceutical reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$16.59, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Takeda Pharmaceutical, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Takeda Pharmaceutical. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- Takeda Pharmaceutical key stats
- Compare share trading platforms
- Is Takeda Pharmaceutical stock a buy or sell?
- Takeda Pharmaceutical performance over time
- Can I short Takeda Pharmaceutical shares?
- Are Takeda Pharmaceutical shares over-valued?
- Takeda Pharmaceutical's financials
- How volatile are Takeda Pharmaceutical shares?
- Does Takeda Pharmaceutical pay a dividend?
- Other common questions
Takeda Pharmaceutical stock price (NYSE:TAK)Use our graph to track the performance of TAK stocks over time.
Takeda Pharmaceutical shares at a glance
|52-week range||US$15.3 - US$19.97|
|50-day moving average||US$16.7969|
|200-day moving average||US$17.1731|
|Dividend yield||US$180 (4.11%)|
|Earnings per share (TTM)||US$1.246|
Where to buy Takeda Pharmaceutical stock
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy Takeda Pharmaceutical stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Considering buying Takeda Pharmaceutical shares?Before you consider Takeda Pharmaceutical, you'll want to hear this.
Ticker Nerd uses advanced software to track hundreds of signals and data points to find stocks before they blow up. You can get the next two hot stocks they find sent to your inbox for free.
Show me how
Takeda Pharmaceutical price performance over time
|1 week (2021-09-16)||-1.80%|
|1 month (2021-08-26)||1.14%|
|3 months (2021-06-25)||-0.24%|
|6 months (2021-03-26)||-11.94%|
|1 year (2020-09-25)||-8.85%|
|2 years (2019-09-26)||-5.11%|
|3 years (2018-09-26)||-22.13%|
|5 years (2016-09-26)||-29.33%|
Is Takeda Pharmaceutical under- or over-valued?
Valuing Takeda Pharmaceutical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Takeda Pharmaceutical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Takeda Pharmaceutical's P/E ratio
Takeda Pharmaceutical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Takeda Pharmaceutical shares trade at around 14x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Takeda Pharmaceutical's PEG ratio
Takeda Pharmaceutical's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.5088. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Takeda Pharmaceutical's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Takeda Pharmaceutical's EBITDA
Takeda Pharmaceutical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$1,031.1 billion (£754.1 billion).
The EBITDA is a measure of a Takeda Pharmaceutical's overall financial performance and is widely used to measure a its profitability.
Takeda Pharmaceutical financials
|Revenue TTM||US$3,345.6 billion|
|Operating margin TTM||16.04%|
|Gross profit TTM||US$2,203.6 billion|
|Return on assets TTM||2.65%|
|Return on equity TTM||8.69%|
|Market capitalisation||US$53.1 billion|
TTM: trailing 12 months
Shorting Takeda Pharmaceutical shares
There are currently 5.8 million Takeda Pharmaceutical shares held short by investors – that's known as Takeda Pharmaceutical's "short interest". This figure is 26.1% up from 4.6 million last month.
There are a few different ways that this level of interest in shorting Takeda Pharmaceutical shares can be evaluated.
Takeda Pharmaceutical's "short interest ratio" (SIR)
Takeda Pharmaceutical's "short interest ratio" (SIR) is the quantity of Takeda Pharmaceutical shares currently shorted divided by the average quantity of Takeda Pharmaceutical shares traded daily (recently around 1.6 million). Takeda Pharmaceutical's SIR currently stands at 3.62. In other words for every 100,000 Takeda Pharmaceutical shares traded daily on the market, roughly 3620 shares are currently held short.
However Takeda Pharmaceutical's short interest can also be evaluated against the total number of Takeda Pharmaceutical shares, or, against the total number of tradable Takeda Pharmaceutical shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Takeda Pharmaceutical's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Takeda Pharmaceutical shares in existence, roughly 0 shares are currently held short) or 0.0018% of the tradable shares (for every 100,000 tradable Takeda Pharmaceutical shares, roughly 2 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Takeda Pharmaceutical.
Find out more about how you can short Takeda Pharmaceutical stock.
Takeda Pharmaceutical share dividends
Dividend payout ratio: 57.38% of net profits
Recently Takeda Pharmaceutical has paid out, on average, around 57.38% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.88% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Takeda Pharmaceutical shareholders could enjoy a 4.88% return on their shares, in the form of dividend payments. In Takeda Pharmaceutical's case, that would currently equate to about $180 per share.
Takeda Pharmaceutical's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Takeda Pharmaceutical's most recent dividend payout was on 14 December 2009. The latest dividend was paid out to all shareholders who bought their shares by 29 March 2021 (the "ex-dividend date").
Takeda Pharmaceutical share price volatility
Over the last 12 months, Takeda Pharmaceutical's shares have ranged in value from as little as US$15.3 up to US$19.97. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Takeda Pharmaceutical's is 1.1209. This would suggest that Takeda Pharmaceutical's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Takeda Pharmaceutical overview
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Albumin/Flexbumin, Ninlaro, and Alunbrig brands. Takeda Pharmaceutical Company has licensing agreements with Denali Therapeutics and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc. and Rani Therapeutics LLC; license and research agreements with The University of Texas MD Anderson Cancer Center and Arrowhead Pharmaceuticals Inc.; research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; HemoShear Therapeutics, LLC; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Takeda Pharmaceutical in the news
Takeda Guilty Of Supply Contract Breach With AbbVie For Prostate Cancer Drug
Takeda Selects Four New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Help Strengthen Health Systems in Low- and Middle-Income Countries
Mirum (MIRM)-Takeda Collaborate for Liver Disease Drug in Japan
Frequently asked questions
More guides on Finder
How to invest in the Cosmos Exploration IPO
Everything we know about the Cosmos Exploration IPO, plus information on how to buy in.
What is behind the bounce in the Zip Co share price?
Shares in BNPL provider Zip Co have slipped more than 13% in the last 6 months.
Why the AGL share price has rebounded today
Shares in electricity giant AGL Energy are down 60% in the last 12 months.
How to invest in the Dundas Minerals IPO
Everything we know about the Dundas Minerals IPO, plus information on how to buy in.
How to invest in the Kalgoorlie Gold Mining IPO
Everything we know about the Kalgoorlie Gold Mining IPO, plus information on how to buy in.
The best iron ore stocks on the ASX (2021)
We look at some of the biggest and best performing iron ore stocks in Australia.
Why are the CBA and WBC share prices stumbling today?
Shares in the major banks have risen more than 50% in the last 12 months.
How to buy Evergrande shares from Australia
Steps to owning and managing China Evergrande Group shares from Australia.
Virgin Tasmania flights sale from $49 and double status credits
Virgin Australia launches more direct Tassie services with flexible flights taking off from October 2021.
How to invest in the Hamelin Gold IPO
Everything we know about the Hamelin Gold IPO, plus information on how to buy in.
Ask an Expert